- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Ajulemic acid.
Displaying page 1 of 1.
EudraCT Number: 2017-003723-29 | Sponsor Protocol Number: JBT101-CF-002 | Start Date*: 2018-05-11 | |||||||||||
Sponsor Name:Corbus Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis (CF) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) HU (Completed) SE (Completed) FR (Completed) PT (Completed) SK (Completed) AT (Completed) BE (Completed) ES (Completed) BG (Completed) NL (Completed) CZ (Completed) GR (Completed) PL (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001762-11 | Sponsor Protocol Number: JBT101-LTS-001 | Start Date*: 2020-08-26 | ||||||||||||||||
Sponsor Name:Corbus Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: An Observational Long-Term Safety Surveillance of Participants from Corbus Sponsored Lenabasum Pivotal Clinical Trials | ||||||||||||||||||
Medical condition: Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) SE (Completed) GB (Completed) AT (Prematurely Ended) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000372-29 | Sponsor Protocol Number: JBT101-SSc-002 | Start Date*: 2018-03-20 | |||||||||||
Sponsor Name:Corbus pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis | |||||||||||||
Medical condition: Systemic Sclerosis (SSc) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003273-10 | Sponsor Protocol Number: JBT101-DM-002 | Start Date*: 2019-05-21 | |||||||||||
Sponsor Name:Corbus Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis | |||||||||||||
Medical condition: Dermatomyositis (DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) CZ (Completed) BG (Completed) SE (Completed) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
